Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
64Cu-ATSM PET/CT in locally advanced rectal cancer
NCT03951337Phase 2Active, not recruiting
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Apr 2019
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of copper-64-diacetyl-bis(N4-methylthiosemicarbazone) in rectal cancer, sponsored by Institut Cancérologique de l'Ouest. Primary endpoint: Relationship between early tumor uptake of 64Cu-ATSM PET/CT images and prediction of histological response at 4 months. Started Apr 2019; status: active, not recruiting.
02
Drugs
copper-64-diacetyl-bis(N4-methylthiosemicarbazone)
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03951337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03951337.